Clinical biotech firm Alector Q3 revenue beats expectations

Alector

06/11/2025 22:15

Overview

Alector Q3 2025 revenue beats analyst expectations despite a year-over-year decline

Net loss for Q3 2025 narrows compared to the same period last year

Company implements 47% workforce reduction to focus on high-priority programs

Outlook

Company anticipates collaboration revenue between $13 mln and $18 mln for 2025

Alector targets IND filing for AL137 in 2026

Independent interim analysis for PROGRESS-AD trial planned for 1H 2026

Result Drivers

ABC PLATFORM - Alector's focus on its proprietary Alector Brain Carrier platform is driving innovation in neurodegenerative disease therapies, per CEO Arnon Rosenthal

Key Details

Metric
Beat/Miss
Actual
Consensus Estimate
Q3 Revenue
Beat
$3.26 mln
$3.02 mln (6 Analysts)
Q3 EPS
-$0.34
Q3 Net Income
-$34.67 mln
Q3 Basic EPS
-$0.34


Analyst Coverage

The current average analyst rating on the shares is "hold" and the breakdown of recommendations is 1 "strong buy" or "buy", 6 "hold" and 2 "sell" or "strong sell"

The average consensus recommendation for the biotechnology & medical research peer group is "buy."

Wall Street's median 12-month price target for Alector Inc is $1.50, about 16.3% above its November 5 closing price of $1.26

Press Release: ID:nGNX3cm25w

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)